MASSIMO MARIA TRUCCO
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD048957L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15213
Personal information
See more information about MASSIMO MARIA TRUCCO at radaris.comName
Address
Phone
4309 Parkman Ave, Pittsburgh, PA 15213
Pittsburgh, PA
4309 Parkman Ave, Pittsburgh, PA 15213
3563 Beechwood Blvd, Pittsburgh, PA 15217
4617 Pine St, Philadelphia, PA 19143
Professional information
Gene Transfer To Pancreatic B Cells For Prevention Of Islet Dysfunction
US Patent:
2002007, Jun 13, 2002
Filed:
May 27, 1999
Appl. No.:
09/320767
Inventors:
NICK GIANNOUKAKIS - PITTSBURGH PA, US
PAUL D. ROBBINS - MY. LEBANON PA, US
MASSIMO TRUCCO - PITTSBURGH PA, US
PAUL D. ROBBINS - MY. LEBANON PA, US
MASSIMO TRUCCO - PITTSBURGH PA, US
International Classification:
A61K048/00, C12Q001/68, C07H021/04
US Classification:
424/085100, 514/044000, 435/006000, 435/091100, 435/375000, 435/325000, 435/455000, 435/320100, 536/023100, 536/024310, 536/024330, 536/024500
Abstract:
The present invention relates to methods and compositions for inhibiting pancreatic cell dysfunction and Fas-mediated apoptosis. The invention relates to recombinant vectors, including viral vectors, comprising nucleic acids molecules encoding inhibitors of interleukin-1 (IL-1) and Fas-mediated apoptosis and the use of such vectors for transfer of said nucleic acid molecules into cells. The invention encompasses genetically engineered cells comprising nucleic acid molecules encoding inhibitors of IL-1 signal transduction. The invention further relates to methods for transplanting such genetically engineered cells into a host recipient with a pancreatic disorder. The methods and compositions of the invention may be used to reduce Il-1 mediated cell dysfunction and apoptosis, thereby reducing the insulitis associated with pancreatic disorders such as insulin dependent diabetes mellitus (IDDM).
Microsphere-Based Composition For Preventing And/Or Reversing New-Onset Autoimmune Diabetes
US Patent:
8389493, Mar 5, 2013
Filed:
May 9, 2011
Appl. No.:
13/103433
Inventors:
Larry R. Brown - Newton MA, US
Nick Giannoukakis - Coraopolis PA, US
Kimberly A. Gillis - Beverly MA, US
Massimo Trucco - Pittsburgh PA, US
Nick Giannoukakis - Coraopolis PA, US
Kimberly A. Gillis - Beverly MA, US
Massimo Trucco - Pittsburgh PA, US
Assignee:
Baxter International Inc. - Deerfield IL
Baxter Healthcare SA - Glattpark (Opfikon)
University of Pittsburgh—of The Commonwealth System of Higher Education - Pittsburgh PA
Baxter Healthcare SA - Glattpark (Opfikon)
University of Pittsburgh—of The Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 2431, 536 241
Abstract:
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Microsphere-Based Composition For Preventing And/Or Reversing New-Onset Autoimmune Diabetes
US Patent:
8022046, Sep 20, 2011
Filed:
Apr 20, 2009
Appl. No.:
12/426904
Inventors:
Larry R. Brown - Newton MA, US
Nick Giannoukakis - Coraopolis PA, US
Massimo Trucco - Pittsburgh PA, US
Nick Giannoukakis - Coraopolis PA, US
Massimo Trucco - Pittsburgh PA, US
Assignee:
Baxter International, Inc. - Deerfield IL
University of Pittsburgh—of the Commonwealth System of Higher Education - Pittsburgh PA
University of Pittsburgh—of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C12N 15/11, C07H 21/02, C07H 21/04
US Classification:
514 44, 536 231, 536 243, 536 2433, 536 245
Abstract:
A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Microsphere-Based Composition For Preventing And/Or Reversing New-Onset Autoimmune Diabetes
US Patent:
7964574, Jun 21, 2011
Filed:
Aug 6, 2007
Appl. No.:
11/834550
Inventors:
Larry R. Brown - Newtown MA, US
Nick Giannoukakis - Coraopolis PA, US
Kimberly A. Gillis - Beverly MA, US
Massimo Trucco - Pittsburgh PA, US
Nick Giannoukakis - Coraopolis PA, US
Kimberly A. Gillis - Beverly MA, US
Massimo Trucco - Pittsburgh PA, US
Assignee:
Baxter International Inc. - Deerfield IL
Baxter Healthcare S.A. - Wallisellen
University of Pittsburgh—of the Commonwealth System of Higher Education - Pittsburgh PA
Baxter Healthcare S.A. - Wallisellen
University of Pittsburgh—of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 2431, 536 241
Abstract:
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Polymers Of Oligonucleotide Probes As The Bound Ligands For Use In Reverse Dot Blots
US Patent:
5683872, Nov 4, 1997
Filed:
Dec 23, 1994
Appl. No.:
8/363585
Inventors:
William A. Rudert - Sarver PA
Massimo Trucco - Pittsburgh PA
Massimo Trucco - Pittsburgh PA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
C12Q 168, C12P 1934
US Classification:
435 6
Abstract:
A method of detecting nucleic acid sequences in which polymers of selected oligonucleotide probes which are complementary to a region in a nucleic acid sequence that is to be detected are bound to a substrate. The polymers bound to the substrate contain multiple randomly repeated copies of a specific oligonucleotide probe and may be synthesized using enzymatic amplification techniques.
Oligonucleotides Targeting Asthma Inflammation Processes
US Patent:
2012014, Jun 7, 2012
Filed:
Oct 25, 2011
Appl. No.:
13/280777
Inventors:
Nick Giannoukakis - Coraopolis PA, US
Massimo Trucco - Pittsburgh PA, US
Wilson Meng - Sewickley PA, US
Massimo Trucco - Pittsburgh PA, US
Wilson Meng - Sewickley PA, US
International Classification:
A61K 9/14, A61P 11/06, A61P 29/00, A61P 11/00, A61K 31/7088, A61K 31/711
US Classification:
424400, 514 44 A
Abstract:
The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation.